Price$14.07+0.05 (+0.36%)
01:45 PM07:30 PM
News · 26 weeks36-43%
2026-02-152026-08-09
Mix1290d
- Insider6(50%)
- Other2(17%)
- Earnings2(17%)
- SEC Filings2(17%)
Latest news
25 items- INSIDERSVP, CFO Fishman Peter L. converted options into 313 units of American Depositary Share and covered exercise/tax liability with 155 units of American Depositary Share, increasing direct ownership by 2% to 7,619 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- SECSEC Form 10-Q filed by Amarin Corporation plc10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECAmarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- PRAmarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market PresenceQ2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation DUBLIN, Ireland and BRIDGEWATER, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the second quarter ended June 30, 2026 (Q2 2026) and highlighted positive outlooks associated with the one-year anniversary of its fully partnered international commercial strategy.
- INSIDEREVP, Chief Scientific Officer Ketchum Steven B converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,887 units of American Depositary Shares, increasing direct ownership by 4% to 42,680 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDEREVP, Chief Operating Officer Keenan David Paul converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,926 units of American Depositary Shares, increasing direct ownership by 15% to 13,470 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSVP, CFO Fishman Peter L. converted options into 2,447 units of American Depositary Shares and covered exercise/tax liability with 1,206 units of American Depositary Shares, increasing direct ownership by 20% to 7,461 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDEREVP, Chief Legal Officer Provoost Jonathan converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,264 units of American Depositary Shares, increasing direct ownership by 110% to 4,624 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- PRAmarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report second quarter 2026 financial results and conduct a conference call on Wednesday, July 29, 2026. The Company will issue a press release detailing its second quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 444188 V
- INSIDERPresident and CEO Berg Aaron converted options into 6,250 units of American Depositary Shares and covered exercise/tax liability with 3,197 units of American Depositary Shares, increasing direct ownership by 4% to 85,648 units (SEC Form 4)4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- PRAmarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment LandscapeDUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) therapies for the treatment of severe hypertriglyceridemia (sHTG), defined as triglycerides (TG) greater than or equal to 500 mg/dL.i These injectable therapies represent meaningful progress for patients at high risk for serious, sometimes life-threatening diseases associated with sHTG, including acute pancreatitis. "The renewed attention triglycerides generated by the introduction of innovative therapies is welcome, as they
- PRNew REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with HypertriglyceridemiaDUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece. The analysis, conducted in the REDUCE-IT placebo arm, evaluated risk-weighted apolipoprotein B (RW-apoB), an integrated metric designed to reflect the relative atherogenicity of apoB-containing lipoproteins. Among statin-treated patients with elevated triglycerides (TG) , RW-apoB was found to more effectively identify individuals at i
- SECAmarin Corporation plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECSEC Form 10-Q filed by Amarin Corporation plc10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
- SECAmarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
- PRAmarin Reports 2026 First Quarter Financial ResultsTotal Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026). "Our results for Q1 2026 reflected the early yet measurable progress generated by
- INSIDERSEC Form 4 filed by Bonfiglio Patrice Eadon4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Cohen Paul4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Sullivan Diane E.4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Sterling Louis Iii4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Horn Keith4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by Odysseas Kostas D4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- INSIDERSEC Form 4 filed by O'Connor Oliver4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
- PRAmarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 543818 Via online
- SECSEC Form DEF 14A filed by Amarin Corporation plcDEF 14A - AMARIN CORP PLC\UK (0000897448) (Filer)
AMRN FAQ
6 questionsWhat does Amarin Corporation plc do?
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the...Where does AMRN stock trade?
Amarin Corporation plc (AMRN) is listed on NASDAQ.What sector and industry is AMRN in?
Amarin Corporation plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AMRN?
Amarin Corporation plc has had 8 recent analyst actions on file. The most recent action was from JP Morgan: Underweight on 2023-11-20.What companies are similar to AMRN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AMRN side-by-side with any of them on Quantisnow.How can I track AMRN on Quantisnow?
Quantisnow aggregates Amarin Corporation plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMRN to receive live email and push alerts on every new disclosure.